BioN­Tech inks can­cer deal with Chi­nese biotech; Eikon, CASI buy Cleave Ther­a­peu­tics’ as­sets

BioN­Tech has reached a re­search and op­tion agree­ment with Bio­theus for two an­ti­body can­di­dates.

Bio­theus an­nounced the deal Wednes­day. It will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.